top of page

DBV Technologies S.A. (DBVT) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DBV Technologies S.A. ("DBV" or "the Company") (NASDAQ: DBVT). The investigation concerns whether DBV and certain of its officers and/or directors have violated federal securities laws.


On October 26, 2021, DBV disclosed that it had “received communication from the FDA [U.S. Food and Drug Administration] concerning [DBV’s] STAMP protocol submission of May 6, 2021.”  DBV advised investors that “[t]he FDA has requested a stepwise approach to DBV’s modified Viaskin Peanut (mVP) development program.  The FDA would like to review the data from DBV’s protein uptake release study prior to providing additional comments on the STAMP protocol design.”  On this news, DBV’s stock price fell sharply during intraday trading on October 27, 2021.


If you are aware of any facts relating to this investigation, or purchased DBV shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

bottom of page